Choosing treatment for patients with bladder cancer combined with prostatic hyperplasia
- Authors: Glybochko P.V1, Alyaev Y.G1, Pshikhachev A.M1, Sorokin N.I1, Dymov A.M1
-
Affiliations:
- I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive Health
- Issue: No 5 (2016)
- Pages: 92-96
- Section: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/286556
- ID: 286556
Cite item
Open Access
Access granted
Abstract
Aim To define treatment selection criteria for patients with bladder cancer combined with benign prostatic hyperplasia (BPH). Materials and methods Between 2006 and 2015, 1148 patients were treated for bladder cancer and 3368 patients for BPH. Among them, 258 (22.5%) patients had both bladder cancer and BPH. 113 (11.6%) patients had indications for surgical treatment of both diseases. In this group, 18 (13.5%) patients also had bladder stones. Only 2 (1.6%) patients had tumor invading the muscle wall, while the remaining patients had non-muscle invasive bladder cancer. Results In 18% of patients the surgery was done in two stages, the first for bladder cancer and the second for BPH. The remaining 82% of patients underwent simultaneous surgery. Bladder cancer recurred in 34.4% of patients. Discussion Comparative evaluation of the results of transurethral resection of the bladder and prostate showed a greater number of intraoperative complications in patients who underwent staged surgery. In our opinion, it may be attributed to the lack of adequate visualization and access to the tumor, located near the opening of the ureter, to the intravesical prostate growth or large median lobe of the prostate. Bladder tumors greater than 3 cm, the multiple lesions and the low tumor differentiation were associated with a higher risk of bladder cancer recurrence, but recurrence rates of simultaneous and staged surgeries were not significantly different. The treatment of patients with bladder cancer in combination with BPH and bladder stones depended on the prostate volume, the number and size of stones. To reduce the risk of complications, in cases with assumed operating time more than 2 hours, it is advisable to split the treatment into two stages with BPH surgery on the second stage.
Full Text
About the authors
P. V Glybochko
I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive HealthDepartment of Urology
Yu. G Alyaev
I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive HealthDepartment of Urology
A. M Pshikhachev
I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive Health
Email: pshich@yandex.ru
PhD, Urologist
N. I Sorokin
I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive Health
Email: nisorokin@mail.ru
Department of Urology
A. M Dymov
I.M. Sechenov First MSMU, Research Institute of Uronephrology and Human Reproductive Health
Email: alimdv@mail.ru
Department of Urology
References
- Dai X., Fang X., Ma Y., Xianyu J. Benign prostatic hyperplasia and the risk of prostate cancer and bladder cancer a meta-analysis of observational studies. Medicine. 2016;95(18):3493.
- Tseng C.H. Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan. BMC Cancer. 2013;13:7.
- Kang D., Chokkalingam A.P., Gridley G., Nyren O., Johansson J.E., Adami H.O., Silverman D., Hsing A.W. Benign prostatic hyperplasia and subsequent risk of bladder cancer. British Journal of Cancer. 2007;96:1475-1479.
- Zhang N.Z., Chen J., Ma L., Xu Z.S. Clinical characteristics of bladder urothelial tumors in male patients the influences of benign prostatic hyperplasia/benign prostatic enlargement. UrolOncol. 2012;30(5):646-651.
- Мартов А.Г., Меринов Д.С., Карагужин С.Г. Одномоментная трансуретральная резекция мочевого пузыря и простаты у больных с сочетанием поверхностного рака мочевого пузыря и доброкачественной гиперплазии простаты. Автореф. дисс. 2004.
- Kevin T., McVary K.T., Claus G. Roehrborn C.G. American Urological Association Guideline 2010: Management of Benign Prostatic Hyperplasia (BPH).
- Duncan W., Quilty P.M. The results of a series of 963 patients with transitional cell carcinoma of the urinary bladder primarily treated by radical megavoltage X-ray therapy. RadiotherOncol. 1986;7(4):299-310.
- Malaveille C., Vineis P., Estéve J., Ohshima H., Brun G., Hautefeuille A., Gallet P., Ronco G., Terracini B., Bartsch H. Levels of mutagens in the urine of smokers of black and blond tobacco correlate with their risk of bladder cancer. Carcinogenesis. 1989;10(3): 577-586.
- Burger M., Catto J.W., Dalbagni G., Grossman H.B., Herr H., Karakiewicz P., Kassouf W., Kiemeney L.A., La Vecchia C., Shariat S., Lotan Y. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2): 234-241.
- Лопаткин Н.А., Даренков С.П., Камалов А.А., Кудрявцев Ю.В., Мартов А.Г. Оперативное лечение опухолей мочевого пузыря. Урология и нефрология. 1999;1:26-31
- Tsivian A., Shtricker A., Sidi A.A. Simultaneous transurethral resection of bladder tumor and benign prostatic hyperplasia: hazardous or a safe timesaver? The journal of urology. 2003;170:2241-2243.
- Ching-Hua Lee, Thomas I.S. Hwang, Chung-HsinYeh. Simultaneous transurethral resection of a bladder tumor and benign prostatic hyperplasia: Four case reports and literature review. Urological Science 2012;23:31e33.
- Kouriefs C., Loizides S., Mufti G. Simultaneous transurethral resection of bladder tumour and prostate: is it safe? Urol Int. 2008;81(2): 125-128.
- Li Z., Hou R., Li J. The efficacy and safety of simultaneous transurethral GreenLightphotoselective vaporization of bladder tumor and prostate in patients with bladder tumor and lower urinary tract symptoms. IntUrolNephrol. 2014;46(4):691-694.
- Li S., Zeng X.T., Ruan X.L., Wang X.H., Guo Y., Yang Z.H. Simultaneous transurethral resection of bladder cancer and prostate may reduce recurrence rates: a systematic review and meta-analysis. Exp Ther Med. 2012;4(4):685-692.
- Redondo-Gonzalez E., de Castro L.N., Moreno-Sierra J., Maestro de las Casas M.L., Vera-Gonzalez V., Ferrari D.G., Corchado J.M. Bladder Carcinoma Data with Clinical Risk Factors and Molecular Markers: A Cluster Analysis. Biomed Res Int. 2015.
- Luo S., Lin Y., Zhang W. Does Simultaneous Transurethral Resection of Bladder Tumor and Prostate Affect the Recurrence of Bladder Tumor? A Meta-Analysis. J. Endourol. 2011;25(2):291-296.
Supplementary files
